QurAlis is proud to sponsor the Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting taking place October 27–30, 2026, in Clearwater, Florida, and online. The Annual NEALS Meeting, organized by the Network of Excellence for ALS, is the premier gathering for the ALS clinical research community - bringing together leading investigators, industry partners, and research professionals to exchange knowledge, drive progress, and accelerate breakthroughs. Results from QurAlis' first-in-human Phase 1 ANQUR clinical trial of QRL-201 in ALS will be featured in a poster presentation on Thursday, October 29, 2026, 4:50-6:30pET (Poster 203, Session 2; location: Opal Sands, Ballroom). QRL-201 is a first-in-class, potent antisense oligonucleotide precision therapeutic in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. STMN2 is a protein important for muscle innervation that is regulated by TDP-43 and downregulated in the majority of ALS patients. ANQUR is the first human trial exploring the hypothesis that restoration of STMN2 may be a suitable disease-modifying approach in ALS. Interim data showed target engagement, biomarker changes suggestive of an effect on disease progression, trend toward slowing of ALSFRS-R decline, and an acceptable safety profile in ALS patients. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases meeting.neals.org/currentmee…

QurAlis Presents! QurAlis' CTO Hagen Cramer and Huijun Tian, director of analytical development and quality control, were featured speakers at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) held last week in Denver. OTS brings together leading researchers and industry experts to advance the field of #oligonucleotide therapeutics. Hagen presented, "CMC workflow – a Phase-Appropriate Strategy and Execution," and Tian presented, "Learnings from Implementing CMC Analytical Control Strategies for Early Stage Oligonucleotide Programs." #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis is proud to sponsor and participate in @alsassociation's Walk to Defeat ALS Boston 2026 to raise funds to provide support to people living with ALS and their families, as well as support #ALS research. QurAlis has participated in this annual Walk for many years as it aligns with our mission to help people living with ALS. The Walk is Sunday, October 25, 2026 at UMass Boston (virtual and in person). The QurAlis Qrew hopes to see you there! #precisionmedicine #neurodegenerativediseases #neurologicaldiseases bit.ly/4i28Av0

QurAlis Presents! Praveen Kumar Pogula, director, drug substance at QurAlis, was a featured speaker at the RNA Leaders USA Congress 2026 held last week during Biotech Week Boston. Praveen presented, “CPPs in Oligonucleotide Manufacturing: Strategies for Control During Scale-Up” as part of the Regulatory and CMC Innovation workshop he co-led with Mayurbhai (Mayur) Patel, vp of CMC and chemistry development at Jude Bio. This workshop session examined current regulatory landscapes, manufacturing complexities, and innovative approaches to overcoming development hurdles. The session was well received and generated an engaging discussion with the audience. Praveen also chaired the "Oligo-Based Therapeutics: Translational & Enabling Platforms" session which featured presentations from Professor Anders Naar, UC Berkeley; Tamar Grossman, CEO of LaJolla Labs; Konstantina Skourti-Stathaki, vp, n-Lorem Foundation; and Yi Lei, senior manager, discovery chemistry project manafgement at WuXi TIDES Discovery.   RNA Leaders Congress focuses on the science and innovation behind RNA technologies, bringing together experts and decisionmakers to explore breakthroughs, and connect, collaborate, and share insights for actionable strategies. Photos top right clockwise: Praveen; Mayur and Praveen; Yi, Mano Manoharan, svp of drug innovation at Alnylam, Konstantina, Praveen; Anders and Praveen. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis Presents! QurAlis' QRL-101 was featured at the 3rd International Kv7 Channels Symposiuim and the KCNQ2 Research Roundtable. Manoj Malhotra, QurAlis' CMO delivered an oral presentation at the KCNQ2 Research Roundtable. At the Kv7 Channels Symposium, Taylor Gray, director, clinical scientist, at QurAlis, delivered an oral presentation on the QRL-101 clinical program, and Manoj and Taylor presented a poster on the QRL-101-05 Phase 1 clinical trial. QRL-101 is QurAlis' potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS. Kv7 is also a clinically validated target to regulate the hyperexcitable state in #epilepsy and QurAlis has expanded the development program for QRL-101 to include epilepsy. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

Excited to have QurAlis' CEO and founder @RoetKasper participate in the Lundbeck External Innovation & Partnering Event held last week in Boston. The Event brought together leaders from across the local innovation ecosystem - including biotech, pharma, venture capital, and academia - for an afternoon of engaging discussions, networking, and opportunities to explore new partnerships. Kasper joined moderator Agne Valentin, director, strategy & operations, Lundbeck and fellow panelists Gregor Macdonald, vp and head of BD&L Search & Assessment at Lundbeck and Stacie Weninger, venture partner at F-Prime Capital, for a discussion about biotech innovation, factors influencing success from early innovation to market, and the value a pharma-biotech collaboration can create. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

We extend our congratulations to Oswald Steward for his receipt of the Kavli Prize, recognizing his groundbreaking discovery that established a core principle in neuroscience: the local synthesis of proteins at synapses governs the development and plasticity of neural connections. Fragile X syndrome fundamentally interferes with this mechanism, as FMRP—the protein deficient in Fragile X—serves as a critical regulator of local RNA translation. Steward's research contributions established the biological framework necessary for comprehending Fragile X as a condition characterized by dysregulation of synaptic protein synthesis and for advancing therapeutic interventions designed to restore normal function. fraxa.org/oswald-steward-win…

QurAlis Presents! Taylor Gray, director, clinical scientist, at QurAlis, presented a poster on the QRL-101-05 Phase 1 clinical trial of QRL-101 at the 16th European Epilepsy Congress: International League Against Epilepsy (ILAE) held last week. QRL-101-05 was a randomized, double-blind, placebo-controlled, three-way crossover clinical trial of QRL-101 in healthy volunteers evaluating biomarkers related to ALS and epilepsy. QRL-101-05 was conducted by the Centre for Human Drug Research (CDHR) in The Netherlands. QRL-201 is QurAlis' potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS. Kv7 is also a clinically validated target to regulate the hyperexcitable state in #epilepsy and QurAlis has expanded the development program for QRL-101 to include epilepsy. Taylor co-presented the poster at ILAE with Marjet Claessens, clinical scientist at CHDR. Photo l-to-r: Marjet, Taylor, Manoj Malhotra, QurAlis' chief medical officer. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis Presents! QurAlis' CEO and founder @RoetKasper today presented a corporate overview at the Wells Fargo Securities 21st Annual Healthcare Conference. Management are also participating in 1:1 investor meetings. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis Presents! QurAlis' CSO Dan Elbaum was a featured speaker at the 6th Oligonucleotides for CNS Summit held last week where he delivered a presentation about the discovery and early development of QRL-201. QRL-201 is QurAlis' first-in-class, potent splice-switching #ASO #precisionmedicine in development to restore STATHMIN-2 (STMN2) expression in #ALS patients with the aim to modify disease progression and improve outcomes. Dan (left) is pictured here with QurAlis' CTO Hagen Cramer. #neurodegenerativediseases #neurologicaldiseases

QurAlis Presents! QurAlis' CEO and founder @RoetKasper will participate at the following investor conferences in September: Wells Fargo Securities 21st Annual Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, H.C. Wainwright 28th Annual Global Investment Conference, 13th Annual World Medical Innovation Forum, and Bank of America Healthcare Trailblazers Private Company Showcase Conference. Management will also participate in 1:1 investor meetings. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases quralis.com/news/quralis-to-…

QurAlis Presents! QurAlis is excited to have our CTO, Hagen Cramer, featured at the 5th Oligonucleotides Analytical Development & CMC Summit held last week. Hagen participated in the panel, "Lessons from a Recently Approved Oligo: What the Data Package & Regulations Actually Looked Like," alongside workshop leaders Shaimaa Ahmadeen, scientific evaluation expert, Saudi FDA; Satya Kuchimanchi, SVP, technical operations, chemistry, manufacturing, & controls at CAMP4 Therapeutics; and Paul Peng, VP, chemistry, manufacturing, & controls at City Therapeutics. Hagen also participated in a fireside chat with Paul entitled, "Evaluating Solid-Phase, Enzymatic, & Liquid-Phase Synthesis Routes to Enable Scalable & Sustainable Oligonucleotide Production." Group photo l-to-r: Paul, Hagen, Satya. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis Presents! Dan Elbaum, QurAlis' CSO, is a featured speaker at the 6th Oligonucleotides for CNS Summit being held August 19-21 in Boston. Dan will present, "The Discovery & Early Development of QRL-201: A Splice Switching ASO Targeting STMN2 for the Treatment of ALS," on Friday, August 21 at 11:00aET. QRL-201 is a first-in-class, potent #ASO #precisionmedicine in development to restore STATHMIN-2 (STMN2) expression in #ALS patients with the aim to modify disease progression and improve outcomes. #neurodegenerativediseases #neurologicaldiseases bit.ly/4q7AGsH

QurAlis Presents! Hagen Cramer, QurAlis' CTO, is a featured speaker at the 5th Oligonucleotides Analytical Development & CMC Summit being held August 17-19 in Boston. Hagen will participate in the panel, "Lessons from a Recently Approved Oligo: What the Data Package & Regulations Actually Looked Like," taking place Monday, August 17 at 1:00-3:30pET. Hagen will also participate in a fireside chat, "Evaluating Solid-Phase, Enzymatic, & Liquid-Phase Synthesis Routes to Enable Scalable & Sustainable Oligonucleotide Production," taking place Tuesday, August 18 at 9:30aET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases oligos-cmc-analytical-develo…

Huge thanks to @EverythingALS for inviting QurAlis’ CEO and founder @RoetKasper to participate in its Digital Endpoints & Biomarkers Summit on July 26–27. Kasper was a featured panelist in the “Accelerating Target Discovery and Translation in the Age of AI” session. It was a robust, engaging discussion about how AI and multimodal data can strengthen target validation and speed the path to new ALS treatments. The discussion also included how the collaboration with the Allen Brain Institute provides a unique opportunity to work together to build an unprecedented multi-layered analysis of ALS in the brain and spinal cord of patients. This project can provide us with an understanding about what causes TDP-43 pathology which will help inform the development of biomarkers and the next generation of therapies for ALS aimed at prevention. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases Panel co-chairs: Fiona Elwood, vp, DAS leader neurodegeneration, neuroscience, Johnson & Johnson and Susan Catalano, Everything ALS board member, CSO. In addition to Kasper, panelists included: Ed Lein, EVP and director, Brain Health Accelerator, Allen Institute for Brain Science; Walter Koroshetz, former director, National Institute of Neurological Disorders and Stroke; Oren Levy, medical director, early clinical development, Regeneron Pharmaceuticals; Brian Winger, associate VP, digital health R&D, Eli Lilly & Company; James Gorman, sr. director of translational R&D, Wyss Institute at Harvard; and Angela Genge, director of clinical research and the Centre for Innovative Medicine, McGill University and CMO, AL-S Pharma.

Today marks #WorldFragileXDay. QurAlis stands with the worldwide #FragileX syndrome (#FXS) community to honor those living with FXS, along with their families and friends affected by this condition. We aim to raise awareness while progressing research toward effective #precisionmedicine treatments and, ultimately, a cure. FXS is a rare genetic #neurologicaldisease recognized as the primary inherited cause of intellectual disability and a known contributor to #autism. Currently, there are no therapies available that modify the disease.

Happy 250th America! QurAlis wishes all a happy, safe, and meaningful #july4th celebration of America's independence!

July marks #NationalFragileXAwarenessMonth and July 22 is World Fragile X Day - dedicated to honoring individuals impacted by Fragile X syndrome (#FXS) and their families. QurAlis stands with the FXS community to promote awareness of the disease and support research focused on creating effective treatments and potentially a cure for this genetic disorder. Throughout this month-long observance, organizations globally engage in fundraising, educational initiatives, and other efforts to improve the lives of those affected by this rare genetic #neurologicaldisease, which is the primary inherited cause of intellectual disability and a recognized contributor to #autism. #precisionmedicine

QurAlis had a successful #ENCALS26! QurAlis' CMO Manoj Malhotra was invited to present our QRL-201 program at the TRICALS Pre-Congress Meeting and members of our clinical team - Nora Hagopian, clinical trial associate, and Taylor Gray, director, clinical scientist - presented posters on updates from our QRL-101 program in #ALS. It was a pleasure to reconnect with friends and former colleagues, meet new people, and engage in valuable scientific discussions as we strive to further research that we believe will significantly impact the lives of individuals with ALS. QurAlis team photo l-to-r: Nora; Manoj; Tracy Kemp, vp of clinical operations; Taylor; Samantha Rubino, director of clinical operations; Dan Elbaum, CSO #precisionmedicine #neurodegenerativediseases #neurologicaldiseases